News & insights

Despite being a preventable and treatable disease, malaria remains a leading cause of illness and death globally with the burden felt most strongly by infants and children in sub-Saharan Africa. To reduce malaria morbidity and mortality in infants and children, Unitaid invested in  Perennial Malaria Chemoprevention (PMC) - which prevents children from getting malaria - through two related projects. These focused on expanding access and adoption of PMC through in-country implementation support and research (the Plus Project) and addressing the need for high-quality supply with a regional manufacturing focus (MMV Supply Project).

CEPA was appointed by Unitaid to undertake the evaluation into Unitaid’s investments in PMC. This independent evaluation used innovative methods to assess the success of the projects overall including relevance, coherence, efficiency, effectiveness, sustainability/ scalability and impact. The evaluation focused strongly on lessons learnt for each of these areas, ensuring relevance of the evaluation, aiming to inform Unitaid’s future projects in this area.

The evaluation had an emphasis on the extent to which the projects have accelerated and advanced the uptake of PMC, recognising the current challenging global health financing environment.

The report has been published by Unitaid and can be accessed here.

The CEPA team responsible for the evaluation included: Kaveri Kumar, Suzanne Fournier, Christian von Drehle, Anisa Hasan-Granier and Giulia Gasparri.